Adicet Bio, Inc. (ACET)

• $1.42

  $1.50

  $1.47
  

  3.4%

  Downside

  Day's Volatility :5.33%

  Upside

  2.0%

  
• $1.05

  $3.77

  $1.47
  

  28.57%

  Downside

  52 Weeks Volatility :72.15%

  Upside

  61.01%

  

Returns

What analysts predicted

Upside of 335.37%

• Orbimed Advisors, LLC

  13.89%

• TANG CAPITAL MANAGEMENT LLC

  9.97%

• RA Capital Management, LLC

  9.15%

• Goldman Sachs Group Inc

  5.20%

• Millennium Management LLC

  4.40%

• Vanguard Group Inc

  3.76%

adicet bio, inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. adicet is developing novel universal immune cell therapies based on gamma delta t cells engineered with chimeric antigen receptors (cars) or t cell receptors (tcrs). adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating tcr-like mabs (tcrls) directed to these cancer-specific peptide targets presented by mhc class i complexes. these tcrls can be used to arm t cells, as t cell engagers or as antibody drug conjugates (adc). in august 2016, adicet entered a strategic collaboration with regeneron pharmaceuticals, inc. to develop next-generation engineered immune-cell therapeutics using adicet’s gamma delta t cell allogeneic platform technology. adicet bio raised $51m in series a financing led by orbimed partners, orbimed israel, novartis v